Small Airways Disease (SAD) in Severe Asthma as a Novel Endpoint and Distinct Target for Mepolizumab (SASAM Study)

NCT05040997 · clinicaltrials.gov ↗
UNKNOWN
Status
40
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS